Brief: Immunome Exclusively Licenses Zentalis Ror1 Antibody-Drug Conjugate

Immunome

08/01/2024 13:46

Jan 8 (Reuters) - Immunome Inc  IMNM.O :
    * IMMUNOME EXCLUSIVELY LICENSES ZENTALIS ROR1 ANTIBODY-DRUG
CONJUGATE AND PROPRIETARY TECHNOLOGY PLATFORM
    * IMMUNOME INC - EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR
PRECLINICAL ROR1 ADC, ON TRACK TO SUBMIT IND IN 1Q 2025
    * IMMUNOME INC - ZENTALIS TO RECEIVE UP-FRONT PAYMENT OF $35
MILLION IN CASH AND IMMUNOME COMMON STOCK
    * IMMUNOME INC - ZENTALIS IS ELIGIBLE TO RECEIVE UP TO $275
MILLION OF MILESTONE PAYMENTS AND MID-TO-HIGH SINGLE-DIGIT
ROYALTIES

Source text for Eikon:  ID:nBw8nsvfQa 
Further company coverage:  IMNM.O 

 ((Reuters.Briefs@thomsonreuters.com;))